Olaratumab’s failure in soft tissue sarcoma

Olaratumab’s failure in soft tissue sarcoma

Soft tissue sarcomas remain one of the rarest malignancies with numerous subtypes that go undiagnosed. The PDGFRα antagonist Olaratumab (Lartruvo) was withdrawn from the market due to disappointing findings in the phase III studies. We share our experience with this medication in a tertiary care cen...

Full description

Bibliographic Details
Main Authors: Maroun Bou Zerdan, Aram H Bidikian, Ibrahim Alameh, Clara El Nakib, Hazem I Assi
Format: Article
Language:English
Published: SAGE Publishing 2021-07-01
Series:Rare Tumors
Online Access:https://doi.org/10.1177/20363613211034115

Similar Items

Similar Items